Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis

Oncogene

Volumn 34, Issue 3, 2015, Pages 385-393

  Heim, D ^a   Cornils, K ^a   Schulze, K ^a   Fehse, B ^a   Lohse, A W ^a   Brummendorf T H ^b   Wege, H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Hepatocarcinogenesis; Hepatocellular carcinoma; Retroviral insertional mutagenesis; Telomerase

Indexed keywords

ANKRD3 PROTEIN, HUMAN; GREEN FLUORESCENT PROTEIN; PROTEIN SERINE THREONINE KINASE; TELOMERASE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL; CELL CLONE; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION; FETUS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSFORMED CELL LINE; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CLONE CELLS; FETUS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GREEN FLUORESCENT PROTEINS; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MUTAGENESIS, INSERTIONAL; PROTEIN-SERINE-THREONINE KINASES; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE; TUMOR SUPPRESSOR PROTEINS;

EID: 84891785762     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.551     Document Type: Article

References (53)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
3. Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis 2008; 29: 1299-1305.
4. Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980; 286: 533-535.
5. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255.
6. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-791.
7. Greider CW. Telomeres. Curr Opin Cell Biol 1991; 3: 444-451.
8. Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 1991; 196: 33-39.
9. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
10. Oh BK, Jo CK, Park C, Kim K, Jung LW, Han KH et al. Telomere shortening and telomerase reactivation in dysplastic nodules of human hepatocarcinogenesis. J Hepatol 2003; 39: 786-792.
11. Oh BK, Kim YJ, Park C, Park YN. Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am J Pathol 2005; 166: 73-80.
12. Takaishi H, Kitamoto M, Takahashi S, Aikata H, Kawakami Y, Nakanishi T et al. Precancerous hepatic nodules had significant levels of telomerase activity determined by sensitive quantitation using a hybridization protection assay. Cancer 2000; 88: 312-317.
13. Hytiroglou P, Kotoula V, Thung SN, Tsokos M, Fiel MI, Papadimitriou CS. Telomerase activity in precancerous hepatic nodules. Cancer 1998; 82: 1831-1838.
14. Kojima H, Yokosuka O, Imazeki F, Saisho H, Omata M. Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease. Gastroenterology 1997; 112 : 493-500.
15. Komine F, Shimojima M, Moriyama M, Amaki S, Uchida T, Arakawa Y. Telomerase activity of needle-biopsied liver samples: its usefulness for diagnosis and judgement of efficacy of treatment of small hepatocellular carcinoma. J Hepatol 2000; 32: 235-241.
16. Wege H, Le HT, Chui MS, Liu L, Wu J, Giri R et al. Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology 2003; 124: 432-444.
17. Haker B, Fuchs S, Dierlamm J, Brummendorf TH, Wege H. Absence of oncogenic transformation despite acquisition of cytogenetic aberrations in long-term cultured telomerase-immortalized human fetal hepatocytes. Cancer Lett 2007; 256: 120-127.
18. Wege H, Heim D, Lütgehetmann M, Dierlamm J, Lohse AW, Brümmendorf TH. Forced activation of beta-catenin signaling supports the transformation of hTERTimmortalized human fetal hepatocytes. Mol Cancer Res 2011; 9: 1222-1231.
19. Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 2004; 32: D523-D527.
20. Hayward WS, Neel BG, Astrin SM. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 1981; 290: 475-480.
21. King W, Patel MD, Lobel LI, Goff SP, Nguyen-Huu MC. Insertion mutagenesis of embryonal carcinoma cells by retroviruses. Science 1985; 228: 554-558.
22. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von KC, Meyer J et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497.
23. Mikkers H, Berns A. Retroviral insertional mutagenesis: tagging cancer pathways. Adv Cancer Res 2003; 88: 53-99.
24. Kustikova O, Fehse B, Modlich U, Yang M, Dullmann J, Kamino K et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005; 308: 1171-1174.
25. Modlich U, Kustikova OS, Schmidt M, Rudolph C, Meyer J, Li Z et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005; 105: 4235-4246.
26. Wahlers A, Schwieger M, Li Z, Meier-Tackmann D, Lindemann C, Eckert HG et al. Influence of multiplicity of infection and protein stability on retroviral vector-mediated gene expression in hematopoietic cells. Gene Ther 2001; 8: 477-486.
27. Baum C, Dullmann J, Li Z, Fehse B, Meyer J, Williams DA et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101: 2099-2114.
28. Kermouni A, Van RE, Arden KC, Vermeesch JR, Weiss S, Godelaine D et al. The IL-9 receptor gene (IL9R): genomic structure, chromosomal localization in the pseudoautosomal region of the long arm of the sex chromosomes, and identification of IL9R pseudogenes at 9qter, 10pter, 16pter, and 18pter. Genomics 1995; 29: 371-382.
29. Weber K, Bartsch U, Stocking C, Fehse B. A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Mol Ther 2008; 16: 698-706.
30. Hoshida Y, Villanueva A, Llovet JM. Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol 2009; 3: 101-103.
31. Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. Hepatology 2006; 43: S145-S150.
32. Keng VW, Villanueva A, Chiang DY, Dupuy AJ, Ryan BJ, Matise I et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 2009; 27: 264-274.
33. Ranzani M, Cesana D, Bartholomae CC, Sanvito F, Pala M, Benedicenti F et al. Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods 2013; 10: 155-161.
34. Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, Zender L et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 2011; 19: 347-358.
35. Gabriel R, Eckenberg R, Paruzynski A, Bartholomae CC, Nowrouzi A, Arens A et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med 2009; 15: 1431-1436.
36. Kustikova OS, Baum C, Fehse B. Retroviral integration site analysis in hematopoietic stem cells. Methods Mol Biol 2008; 430: 255-267.
37. Astrom A, D'Amore ES, Sainati L, Panarello C, Morerio C, Mark J et al. Evidence of involvement of the PLAG1 gene in lipoblastomas. Int J Oncol 2000; 16: 1107-1110.
38. Astrom AK, Voz ML, Kas K, Roijer E, Wedell B, Mandahl N et al. Conserved mechanism of PLAG1 activation in salivary gland tumors with and without chromosome 8q12 abnormalities: identification of SII as a new fusion partner gene. Cancer Res 1999; 59: 918-923.
39. Declercq J, Van DF, Braem CV, Van V IC, Voz M, Wassef M et al. Salivary gland tumors in transgenic mice with targeted PLAG1 proto-oncogene overexpression. Cancer Res 2005; 65: 4544-4553.
40. Hibbard MK, Kozakewich HP, Dal CP, Sciot R, Tan X, Xiao S et al. PLAG1 fusion oncogenes in lipoblastoma. Cancer Res 2000; 60: 4869-4872.
41. Kas K, Voz ML, Roijer E, Astrom AK, Meyen E, Stenman G et al. Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations. Nat Genet 1997; 15: 170-174.
42. Landrette SF, Kuo YH, Hensen K, Barjesteh van Waalwijk van Doorn-Khosrovani S, Perrat PN, Van de Ven WJ et al. Plag1 and Plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11. Blood 2005; 105: 2900-2907.
43. Zatkova A, Rouillard JM, Hartmann W, Lamb BJ, Kuick R, Eckart M et al. Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma. Genes Chromosomes Cancer 2004; 39: 126-137.
44. Meylan E, Martinon F, Thome M, Gschwendt M, Tschopp J. RIP4 (DIK/PKK), a novel member of the RIP kinase family, activates NF-kappa B and is processed during apoptosis. EMBO Rep 2002; 3: 1201-1208.
45. Kim SW, Oleksyn DW, Rossi RM, Jordan CT, Sanz I, Chen L et al. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells. Blood 2008; 111: 1644-1653.
46. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-260.
47. Lenardo MJ, Baltimore D. NF-kappa B a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989; 58: 227-229.
48. Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996; 87: 565-576.
49. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996; 274: 787-789.
50. Wang CY, Mayo MW, Baldwin Jr AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784-787.
51. Luedde T, Beraza N, Kotsikoris V, van LG, Nenci A, De VR et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11: 119-132.
52. Kustikova OS, Wahlers A, Kuhlcke K, Stahle B, Zander AR, Baum C et al. Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 2003; 102: 3934-3937.
53. Kuhlcke K, Fehse B, Schilz A, Loges S, Lindemann C, Ayuk F et al. Highly efficient retroviral gene transfer based on centrifugation-mediated vector preloading of tissue culture vessels. Mol Ther 2002; 5: 473-478.